Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions

References

• ABEL, S. M., MAGGS, J. L., BACK, D. J. and PARK, B. K., 1992, Cortisol metabolism by human liver in vitro—I. Metabolite identification and inter-individual variability. Journal of Steroid Biochemistry and Molecular Biology, 43, 713–719.
   PubMedGoogle Scholar
• AHONEN, J., OLKKOLA, K. T. and NEUVONEN, P. J., 1995, Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology, 40, 270–272.
   PubMed Web of Science ®Google Scholar
• ANDERSSON, T., MINERS, J. 0., VERONESE, M. E. and BIRKETT, D. J., 1994, Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. British Journal of Clinical Pharmacology, 37, 597–604.
   Google Scholar
• BACIEWICZ, A. M. and BADEwicz, F. A., 1993, Ketoconazole and fluconazole drug interactions. Archives of Internal Medicine, 153, 1970–1976.
   PubMedGoogle Scholar
• BACK, D. J. and TM, J. F., 1991, Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. British Journal of Clinical Pharmacology, 32, 624–626.
   PubMed Web of Science ®Google Scholar
• BADER, A., KNOP, E., BoKER, K. H. W., CROME, 0., FREHAUF, N., GONSCHIOR, A. K., CHRISTIANS, U., ESSELMANN H., PICHLMAYR, R. and SEWING, K. F., 1996, Tacrolimus (FK 506) biotrans-formation in primary rat hepatocytes depends on extracellular matrix geometry. Naunyn-Schmiedeberg' s Archive of Pharmacology, 353, 461–473.
   Google Scholar
• BADER, A., ZECH, K., CROME, 0., CHRISTIANS, U., RINGE, B., PICHLMAYR, R. and SEWING, K.-F. R., 1994, Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals. Xenobiotka, 24, 623–633.
   Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARICE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BIRKETT, D. J., MACKENZIE, P. I., VERONESE M. E. and MINERS, J. 0., 1993, In vitro approaches can predict human drug metabolism. Trends in Pharmaceutical Science, 14, 292–294.
   Google Scholar
• BLACK, D. J., KUNZE, K. L., WIENKERS, L. C., GIDAL, B. E., SEATON, T. L., MCDONNELL, N. D., EVANS, J. S., BAUWENS J. E. and TRAGER, W. F., 1996, Warfarin-Fluconazole II. A metabolically based drug interaction: In vivo studies. Drug Metabolism and Disposition, 24, 422–428.
   Google Scholar
• BLUM, R. A., WILTON, J. H., HILLIGOSS, D. H., GARDNER, M. J., HENRY, E. B., HARRISON, N. J. and SCHENTAG J. J., 1991, Effect of fluconazole on the disposition of phenytoin. Clinical Pharmacology and Therapeutics, 49, 420–425.
   Google Scholar
• Como, J. A. and DismuxEs, W. E., 1994, Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine, 330, 263–272.
   PubMed Web of Science ®Google Scholar
• DAYER, P., LEEMANN, T. and STRIBERNI, R., 1989, Dextromethorphan 0-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 db activity. Clinical Pharmacology and Therapeutics, 45, 34–40.
   PubMed Web of Science ®Google Scholar
• DE WIT, S., O'DOHERTY, E., EDWARDS, J., YATES, R., SMITH, R. P. and CLumEcx, A. N., 1998, Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a Phase I study. Antimicrobial Agents and Chemotherapy, 42, 903–906.
   Google Scholar
• GUENGERICH, P. F., ENOCH, M. D. and BLAIR, I. D., 1986, Oxidation of quinidine by human liver cytochrome P450. Molecular Pharmacology, 30, 287–294.
   PubMed Web of Science ®Google Scholar
• HONIG, P. K., WORTHAM, D. C., ZAMANI, K., CONNER, D. P., MULLIN, J. C. and CANTILENA, L. R., 1993, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic conse-quences. Journal of the American Medical Association, 269, 1513–1518.
   PubMed Web of Science ®Google Scholar
• HOSTETLER, K. A., WRIGHTON, S. A., MOLOWA, D. T., THOMAS, P. E., LEVIN, W. and GUZELIAN, P. S., 1989, Coinduction of multiple cytochrome P450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Molecular Pharmacology, 35, 279–285.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B., HUMPHREY, M. J., MATTHEW, D. E. and TARBIT, M. H., 1988, Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic monooxygenase activity. Biochemical Pharmacology, 37, 401–408.
   PubMedGoogle Scholar
• KNOP, E., BADER, A., BöKER, K., PICHLMAYR, R. and SEWING, K. F., 1995, Ultrastructural and functional differentiation of hepatocytes under long-term culture conditions. The Anatomical Record, 242, 337–349.
   PubMedGoogle Scholar
• KRAmER, M. R., MARSHALL, S. E., DENNING, D. W., KEOGH, A. M., TucRER, R. M., GALGIANI, J. N., STEVENS, D. A. and THEODORE, J., 1990, Cyclosporine and itraconazole interaction in heart and lung-transplant recipients. Annals of Internal Medicine, 113, 327–329.
   PubMed Web of Science ®Google Scholar
• KRISHNAIAH, Y. S. R., SATYANARAYANA, S. and VISWESWARAM, D., 1994, Interaction between tol-butamide and ketoconazole in healthy subjects. British Journal of Clinical Pharmacology, 37, 205–207.
   Google Scholar
• KUNZE, K. L., WlENKERS, L. C., THUMMEL, and TRAGER, W. F., 1996, Warfarin-Fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metabolism and Disposition, 24, 414–421.
   PubMed Web of Science ®Google Scholar
• LAVRUSEN, K., VAN HOUDT, J., THUS, D., MEULDERMANS, W. and HEYKANTS J., 1986, Induction potential of antifungals containing an imidazole or triazole moiety. Biochemical Pharmacology, 35, 1867–1878.
   Google Scholar
• LAVRUSEN, K., VAN HOLTDT, J., THUS, D., MEULDERMANS, W. and HEYKANTS J., 1987, Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotka, 17, 45–57.
   Google Scholar
• LAVRUSEN, K. L. M., VAN HOUDT, J. M. G., VAN DYCK, D. M. J., MEULDERMANS, W. E.G. and HEYKANrs, J. J. P., 1990, Induction potential of fluconazole toward drug-metabolising enzymes in rats. Antimicrobial Agents and Chemotherapy, 34, 402–408.
   Google Scholar
• LAZAR, J. D. and WILNER, K. D., 1990, Drug-interactions with fluconazole. Reviews of Infectious Diseases, 12, S327–333.
   PubMedGoogle Scholar
• McKILLoR, D., 1985, Effects of phenobarbitone and f3-naphthoflavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochemical Pharmacology, 34, 3137–3142.
   PubMedGoogle Scholar
• MEREDITH, C. G., MALDOADO, A. L. and SPEEG, K. V. JR, 1985, The effect of ketoconazole 011 hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metabolism and Disposition, 13, 156–162.
   PubMed Web of Science ®Google Scholar
• MEIER, U. T., KRONBACH, T. and MEYER, U. A., 1985, Assay of mephenytoin metabolism in human microsomes by high performance liquid chromatography. Analytical Biochemistry, 151, 286–291.
   PubMedGoogle Scholar
• MINERS, J. 0., SMITH, K. J., ROBSON, R. A., McMANus, M. E., VERONESE, M. E. and BIRICETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Biochemical Pharmacology, 37, 1137–1144.
   Google Scholar
• NAVJAR, L. K., CORREA, A., JAMES, P., LUTHER, M. F. and GRAYBILL, J. R., 1996, D0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans. Journal of Antimicrobial Chemotherapy, 38, 671–677.
   PubMedGoogle Scholar
• NEWMAN, S. L. and GUZELIAN, P. S., 1983, Identification of the cyanopregnenolone-inducible form of hepatic cytochrome P450 as a catalyst of aldrin epoxidation. Biochemical Pharmacology, 32, 1529–1531.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OLKKOLA, K. T., BACKMAN, J. T. and NEUVONEN, P. J., 1994, Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 55, 481–485.
   PubMed Web of Science ®Google Scholar
• PARKINSON, A., CLEMENT, R. P., CASCIANO, C. N. and CAYEN, M. N., 1992, Evaluation of loratidine as an inducer of liver microsomal cytochrome P450 in rats and mice. Biochemical Pharmacology, 43, 2169–2180.
   PubMed Web of Science ®Google Scholar
• PECK, J. J., TEMPLE, R. and COLLINS, J. M., 1993, Understanding consequences of concurrent therapies. Journal of the American Medical Association, 269, 1550–1552.
   Web of Science ®Google Scholar
• POHJOLA -SINTONEN, S., VIITASALO, M., TOIVONEN, L. and NEUVONEN, P., 1993, Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology, 45, 191–193.
   PubMedGoogle Scholar
• PURBA, H. S., MAGGS, J. L., ORME, M. L. E., BACK, D. J. and PARK, B. K., 1987, The metabolism of 17a-ethinyloestradiol by human liver microsomes : formation of catechol and chemically reactive metabolites. British Journal of Clinical Pharmacology, 23, 447–453.
   Google Scholar
• RAMZAN, I. and CHAN, M., 1993, Influence of fluconazole on antipyrine kinetics in rats. European Journal of Drug Metabolism and Pharmacokinetics, 18, 273–276.
   PubMedGoogle Scholar
• REESE, J. A. and BYARD, J. L., 1981, Isolation and culture of adult rat hepatocytes from liver biopsies. In vitro, 17, 935–941.
   PubMedGoogle Scholar
• RING, B. J., BINKLEY, S. N., VANDENBRANDEN, M. and WRIGHTON, S. A., 1996, In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A British Journal of Clinical Pharmacology, 41, 181–186.
   Google Scholar
• RITTER, J. K. and FRANKLIN, M. R., 1987, High magnitude hepatic cytochrome P450 induction by an N- substitute d imidazole antimycotic, clotrimazole. Biochemical Pharmacology, 36, 2783-2787. RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochemical Pharmacology, 48, 2147–2156.
   Google Scholar
• RODRIGUES, A. D., LEWIS, D. F. V., IOANNIDES, C. and PARKE, D. V., 1987, Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P450. Xenobiotka, 17, 1315–1327.
   Google Scholar
• SHEETS, J. J. and MASON, J. I., 1984, Ketoconazole : A potent inhibitor of cytochrome P450-dependent drug metabolism in rat liver. Drug Metabolism and Disposition, 12, 603–606.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., DOECKE, C. J., MCMANUS, M. E., SANSOM, L. N. and MINERS, J. 0., 1992, Co-regulation of phenytoin and tolbutamide metabolism in humans. British Journal of Clinical Pharmacology, 34, 494–498.
   Google Scholar
• THomsoN, R. G., RAWLINS, M. D., JAS, 0. F. W., WOOD, P. and WILLIAMS, F. M., 1988, The acute and subchronic effects of ketoconazole on hepatic microsomal monooxygenases in the rat. Biochemical Pharmacology, 37, 3975–3980.
   Google Scholar
• TJIA, J. F., COLBERT, J. and BACK, D. J., 1996, Theophylline metabolism in human liver microsomes : Inhibition studies. Journal of Pharmacology and Experimental Therapeutics, 276, 912–917.
   PubMed Web of Science ®Google Scholar
• TOUCHETTE, M. A., CHANDRASEKAR, P. H., MILAD, M. A. and EDWARDS, D. J., 1992, Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. British Journal of Clinical Pharmacology, 34, 75–78.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., KUWABARA, T., CHuN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOOSSCHE, H., WILLEMSENS, G., COOLS, W., CORNELLISSEN, F., LAUWERS, W. F. and VAN CUTSEM J. M., 1980, In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrobial Agents and Chemotherapy, 17, 922–928.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994a, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. Journal of Clinical Pharmacology, 34, 1222–1227.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU -BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994b, Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23–31.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994c, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics, 268, 1278–1283.
   Google Scholar
• WALLE, T., KUMAR, G. N., MCMILLAN, J. M., THORNBURG, K. R. and WALLE, U. K., 1993, Taxol metabolism in rat hepatocytes. Biochemical Pharmacology, 46, 1661–1664.
   PubMed Web of Science ®Google Scholar
• WOLFF, T. and GUENGERICH, F. P., 1988, Rat liver cytochrome P450 isozymes as catalysts of aldrin epoxidation in reconstituted monooxygenase systems and microsomes. Biochemical Pharmacology, 36, 2581–2588.
   Google Scholar
• WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTlE, A. E. and CASHMAN, J. R., 1993, In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metabolism Reviews, 25, 453–484.
   PubMed Web of Science ®Google Scholar
• YAMADA, H., TSUDA, T., WATANABE, T., OHASHI, M., MURAKAMI, K. and MOCHIZUKI, H., 1993, In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrobial Agents and Chemotherapy, 37, 2412–2417.
   PubMedGoogle Scholar